Efficacy of Talazoparib in Asian Metastatic Breast Cancer Patients With a Homologous Recombinant Deficiency (HRD) Signature

Clinical trial NCT05288127 · UNKNOWN

Trial details

NCT number: NCT05288127
Sponsor: University of Malaya
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

HRD 100 Gene Expression High Triple Negative Breast Cancer

Start date: 2022-03-08
Primary completion: 2024-06-01
Enrollment: 55

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.